http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
주의력결핍-과잉운동장애의 비중추신경흥분제 치료의 최신지견
반건호,손소정,이서경,강원섭,조아랑,박진경 경희대학교 2006 慶熙醫學 Vol.22 No.1
Methylphenidate (MPH), amphetamine, and pemoline are cerebrostimulants that have been commonly prescribed for more than half century in the treatment of attention-deficit/hyperactivity disorder (ADHD). The use of such drugs, however, is often followed by untoward effects such as loss of appetite, insomnia, nausea, abdominal pain, vomiting, irritability, and etc. There are also debates about decrements in height and weight percentiles and drug dependency. Thus, in this study, we discussed new therapeutic drugs, non cerebro-stimulants, with possibly less adverse effects and more efficacies. Atomoxetine, highly selective inhibitor of the presynaptic noradrenaline transporter with little or no affinity for other neurotransmitter transporters and receptors, is a non-excitatory drug with a strong possibility to replace CNS excitatory drugs. It is also safer in relation to drug dependency since it does not affect nucleus accumbens or the striatum. Atomoxetine, therefore, can be used in patients who do not respond to the CNS excitatory drugs. Tricyclic antidepressants, imipramine and desipramine are also most extensively studied drugs as ADHD treatment modalities. They also exert inhibitory effect on the reuptake of norepinephrine. The use of these drugs in children, however, is limited because of cardiovascular effects. Bupropion is one of promising drugs in treating prepubertal children with ADHD. It is also useful for comorbid depression and conduct problems. Increasing attention is being given to a narcolepsy drug, modafinil. Modafinil acts on histamine pathway resulting in wakefulness. This effect is similar to that of neuropeptide orexin. Since the effect of modafinil is independent of catecholamine, drug dependency adverse effect is not expected. Recently, some new drugs, such as reboxetine, are reported as safe and efficacious for children with ADHD, but they need long-term safety and controlled studies.
Yun Sojeong,Ryu Ji Hyeong,Jang Joo Hee,Bae Hyunjoo,Yoo Seung-Hyo,Choi Ae-Ran,Jo Sung Jin,Lim Jihyang,Lee Jehoon,Ryu Hyejin,Cho Sung-Yeon,Lee Dong-Gun,Lee Jongmin,Kim Seok Chan,Park Yeon-Joon,Lee Hyeyo 대한진단검사의학회 2021 Annals of Laboratory Medicine Vol.41 No.6
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody assays have high clinical utility in managing the pandemic. We compared antibody responses and seroconversion of coronavirus disease 2019 (COVID-19) patients using different immunoassays. Methods: We evaluated 12 commercial immunoassays, including three automated chemiluminescent immunoassays (Abbott, Roche, and Siemens), three enzyme immunoassays (Bio-Rad, Euroimmun, and Vircell), five lateral flow immunoassays (Boditech Med, SD biosensor, PCL, Sugentech, and Rapigen), and one surrogate neutralizing antibody assay (GenScript) in sequential samples from 49 COVID-19 patients and 10 seroconversion panels. Results: The positive percent agreement (PPA) of assays for a COVID-19 diagnosis ranged from 84.0% to 98.5% for all samples (>14 days after symptom onset), with IgM or IgA assays showing higher PPAs. Seroconversion responses varied across the assay type and disease severity. Assays targeting the spike or receptor-binding domain protein showed a tendency for early seroconversion detection and higher index values in patients with severe disease. Index values from SARS-CoV-2 binding antibody assays (three automated assays, one LFIA, and three EIAs) showed moderate to strong correlations with the neutralizing antibody percentage (r=0.517–0.874), and stronger correlations in patients with severe disease and in assays targeting spike protein. Agreement among the 12 assays was good (74.3%–96.4%) for detecting IgG or total antibodies. Conclusions: Positivity rates and seroconversion of SARS-CoV-2 antibodies vary depending on the assay kits, disease severity, and antigen target. This study contributes to a better understanding of antibody response in symptomatic COVID-19 patients using currently available assays.
Yi, SoJeong,Kim, Sung Eun,Park, Min-Kyu,Yoon, Seo Hyun,Cho, Joo-Youn,Lim, Kyoung Soo,Shin, Sang-Goo,Jang, In-Jin,Yu, Kyung-Sang Adis International 2012 BioDrugs Vol.26 No.3
<P>HD203 is a biosimilar of etanercept, a fusion protein of the ligand-binding portion of the human tumor necrosis factor receptor II linked to the Fc portion of human immunoglobulin G1. Since HD203 is under clinical development, this study was conducted to compare the pharmacokinetics of HD203 with Enbrel®, the first marketed etanercept.</P>
Yi, SoJeong,Cho, Joo-Youn,Lim, Kyoung Soo,Kim, Kyu-pyo,Kim, JaeWoo,Kim, Bo-Hyung,Hong, Jang-hee,Jang, In-Jin,Shin, Sang-Goo,Yu, Kyung-Sang Blackwell Publishing Ltd 2009 Basic & Clinical Pharmacology & Toxicology Vol.105 No.4
<P>Abstract: </P><P>Three kinds of herbal medicines, commonly used in Korea, <I>Angelicae tenuissima radix</I>, <I>Angelicae dahuricae radix</I> and <I>Scutellariae radix</I> were studied to evaluate their effect on cytochrome <I>P450</I> (CYP) activities in healthy volunteers. A total of 24 healthy male volunteers were assigned to one of three parallel herbal treatment groups, each consisting of eight volunteers. A cocktail of probe drugs for CYP enzymes was orally administered before and after multiple administrations of herbal medicines, three times a day for 13 days. Probe drugs used to measure CYP activities were caffeine (CYP1A2), losartan (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), chlorzoxazone (CYP2E1) and midazolam (CYP3A4). The probe drugs and their metabolites were quantified in plasma or urine using HPLC or LC-MS/MS. Changes in each CYP activity was evaluated by metabolic ratio of the probe drug (concentration ratio of metabolite to parent form at reference time point) following the herbal medication period, compared to the baseline values. <I>A. dahuricae radix</I> significantly decreased CYP1A2 activity to 10% of baseline activity (95% CI: 0.05–0.21). <I>S. radix</I> also showed significant changes in CYP2C9 and CYP2E1 activities. Compared to baseline values, the metabolic activities of losartan were decreased to 71% (0.54–0.94). In addition, <I>S. radix</I> showed a 1.42-fold (1.03–1.97) increase in chlorzoxazone metabolic activity. However, CYP activities were not meaningfully influenced by <I>A. tenuissima radix</I>. Changes in certain CYP activities were observed after the administration of <I>S. radix</I> and <I>A. dahuricae radix</I> in healthy volunteers. Therefore, herbal medicines containing <I>S. radix</I> or <I>A. dahuricae radix</I> are candidates for further evaluation of clinically significant CYP-mediated herb-drug interactions in human beings.</P>
윤수민,SoJeong Yi,Su-jin Rhee,이현아,김윤,Kyung-Sang Yu,Jae-Yong Chung 대한임상약리학회 2019 Translational and Clinical Pharmacology Vol.27 No.3
This study aimed to assess the pharmacokinetics of cyclosporine A (CsA) in Asian children with renal impairment (RI) by developing a physiologically-based pharmacokinetic (PBPK) model with Simcyp Simulator. The PBPK model of Asian children with RI was developed by modifying the physiological parameters of the built-in population libraries in Simcyp Simulator. The ratio of healthy and RI populations was obtained for each parameter showing a difference between the populations. Each ratio was multiplied by the corresponding parameter in healthy Asian children. The model verification was performed with published data of Korean children with kidney disease given multiple CsA administrations. Simulations were performed with different combinations of ethnicity, age, and renal function to identify the net impact of each factor. The simulated results suggested that the effect of RI was higher in children than adults for both Caucasian and Asian. In conclusion, the constructed model adequately characterized CsA pharmacokinetics in Korean children with RI. Simulations with populations categorized by ethnicity, age, and renal function enabled to assess the net impact of each factor on specific populations.
Test and Simulation for the Response of PLS-II Button Type Beam Position Monitor
Lee, Sojeong,Hong, Juho,Ko, In Soo,Kim, Changbum,Kim, Do Tae,Park, Hong Jib,Lee, Eun Hee,Lee, Jin Won,Kim, Seunhwan,Park, Yong-jung,Park, Sung-Ju Korean Physical Society 2011 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.59 No.2
Yi, SoJeong,Jeon, Hyewon,Yoon, Seo Hyun,Cho, Joo-Youn,Shin, Sang-Goo,Jang, In-Jin,Yu, Kyung-Sang Lippincott Williams Wilkins, Inc. 2012 Journal of cardiovascular pharmacology Vol.59 No.4
ABSTRACT:: Tolvaptan is a selective arginine vasopressin V2-receptor antagonist that is used as an aquaretic agent. This trial investigated the pharmacokinetics and pharmacodynamics of 15- to 60-mg single oral doses of tolvaptan in healthy Korean men. A dose block–randomized, placebo-controlled, double-blind, single ascending dose trial was conducted with 46 subjects receiving tolvaptan (15, 30, or 60 mg) or placebo. To determine pharmacokinetics and pharmacodynamics, blood and urine samples were collected at baseline and up to 48 hours after drug administration. Urine volume and fluid intake were measured for 24 hours starting the day before dosing (day −1) as baseline, and on the day of drug administration (day 1). Tolvaptan showed dose-linear pharmacokinetic characteristics regarding area under the concentration–time curve. Changes from baseline in 24-hour urine volume and 24-hour fluid balance correlated significantly with area under the concentration–time curve from time 0 to the last measurable time. Dose-dependent increases were observed in serum osmolality, serum sodium concentration, and free water clearance in the 4- to 8-hour interval after dosing, and these increases were maintained for at least 24 hours. Single 15- to 60-mg doses of tolvaptan exhibited linear pharmacokinetics and resulted in substantial, dose-dependent aquaresis in healthy Korean men.